BiotechTube
TrAMPoline Pharma

TrAMPoline Pharma

Cambridge, United States· Est.
trampolinepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

TrAMPoline Pharma is a private, preclinical-stage biotech founded in 2019 and based in Cambridge, MA, with a research facility in Aurora, CO. The company is pioneering next-generation TIL therapies for solid tumors using its patented coR8:Amp™ gene engineering platform, which is designed to boost T cell potency, persistence, and polyclonality. Its lead program, MightyTIL™, has shown superior anti-tumor activity in animal models compared to conventional TILs, positioning it to address the significant unmet need in solid tumors where many immunotherapies fail. The company is led by a seasoned team with deep expertise in immunotherapy and biotech entrepreneurship.

OncologySolid Tumors

Technology Platform

coR8:Amp™ - A synthetic fusion gene combining CD8α (for enhanced TCR binding) and MyD88 (for amplified TCR signaling) engineered into Tumor-Infiltrating Lymphocytes (TILs) to create enhanced MightyTIL™ therapies.

Opportunities

The significant unmet need in solid tumors, which constitute ~90% of cancers, presents a massive market opportunity.
The company's polyclonal MightyTIL approach could address key limitations of current single-antigen therapies (like antigen escape) and toxicities associated with high-dose IL-2, potentially offering a differentiated and best-in-class profile.

Risk Factors

Key risks include the high failure rate of preclinical-to-clinical translation, intense competition in the cell therapy space, challenges in scaling autologous manufacturing, and the substantial capital requirements to advance through clinical trials without current revenue.

Competitive Landscape

TrAMPoline competes in the rapidly evolving TIL and solid tumor cell therapy arena. Direct competitors include Iovance Biotherapeutics (commercial TIL leader), Instil Bio, and Turnstone Biologics, as well as numerous companies developing next-generation CAR-T and TCR therapies for solid tumors. Differentiation hinges on the efficacy of the coR8:Amp™ enhancement.

More companies in Cell & Gene Therapy →More companies in United States →